Press Releases

15 Jul '21
WALTHAM, Mass., July 15, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (TScan), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of its initial public...
Additional Formats
25 Jan '21
Funds and accounts managed by BlackRock and RA Capital Management join two other healthcare-focused funds and current investors. Proceeds to support continued development of TCR-T cell therapy pipeline WALTHAM, Mass. – (BUSINESS WIRE) – TScan Therapeutics, a biopharmaceutical company focused on the...
Additional Formats